Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Preclinical services company Charles River (CRL) will acquire CRO Inveresk Research Group (IRGI) in a stock and cash deal worth $1.5 billion based on CRL's June 30 closing price
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury